Sugi Predict

Sugi Predict / Compounds / SCHEMBL199415

SCHEMBL199415

SCHEMBL199415

CC(C)(C)OC(=O)N[C@@H](Cc1ccc([N+](=O)[O-])cc1)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 5/20 0.68
▸ PPARG P37231 4/20 0.68
▸ ACE P12821 1/20 0.58
▸ ITGB3 P05106 2/20 0.57
▸ ITGA2B P08514 2/20 0.57
▸ CA2 P00918 1/20 0.54
▸ CTSS P25774 6/20 0.52
▸ CTSK P43235 5/20 0.52
▸ CTSL P07711 1/20 0.51
▸ CTSB P07858 1/20 0.51
▸ ITGA4 P13612 2/20 0.51
▸ ITGB7 P26010 2/20 0.51
▸ PTPN1 P18031 2/20 0.49
▸ ITGB1 P05556 1/20 0.48
▸ ITGAV P06756 1/20 0.48
▸ ITGB5 P18084 1/20 0.48
▸ PPARD Q03181 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL441283 1.00 PPARA (0.68) PPARAPPARGACEITGB3ITGA2B
SCHEMBL440723 1.00 PPARA (0.68) PPARAPPARGACEITGB3ITGA2B
SCHEMBL4797933 0.94 PPARG (0.62) PPARAPPARGACEITGB3ITGA2B
SCHEMBL4094724 0.94 PPARG (0.62) PPARAPPARGACEITGB3ITGA2B
SCHEMBL8976947 0.93 PPARA (0.60) PPARAPPARGACEITGB3ITGA2B
SCHEMBL3821796 0.92 PPARA (0.60) PPARAPPARGACEITGB3ITGA2B
SCHEMBL20187250 0.90 CTSS (0.61) PPARAPPARGACEITGB3ITGA2B
SCHEMBL3840582 0.90 PPARG (0.58) PPARAPPARGACEITGB3ITGA2B
SCHEMBL18228983 0.90 CTSS (0.61) PPARAPPARGACEITGB3ITGA2B
SCHEMBL10034081 0.90 PPARG (0.60) PPARAPPARGACEITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1029 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114539158-B FXIa inhibitor compound and preparation method and application thereof 沈阳药科大学 2023-12-08 — — CN claimed
CN-114539158-A FXIa inhibitor compound and preparation method and application thereof 沈阳药科大学 2022-05-27 — — CN claimed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 — — US claimed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 — — EP claimed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 — — WO claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 — — US claimed
EP-1157004-A1 REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES IDEC PHARMACEUTICALS CORPORATION (US) 2001-11-28 — — EP claimed
US-6207858-B1 ELIMINATES THE NEED FOR ION EXCHANGE CHROMOTOGRAPHIC SEPARATION OF INTERMEDIATES, USEFUL AS BI-FUNCTIONAL CHELATORS IN RADIOIMMUNOTHERAPY AND IMAGING, DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA), SUITABLE FOR IDEC PHARMACEUTICALS CORPORATION 2001-03-27 — — US claimed
WO-2000051976-A1 REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES IDEC PHARMACEUTICALS CORPORATION (US) 2000-09-08 — — WO claimed
US-12624122-B2 Affinity maturated TAG72 specific single chain antibodies H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2026-05-12 — — US disclosed
US-12612598-B2 Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy IOVANCE BIOTHERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 — — EP disclosed
EP-4720089-A1 COMPOSITIONS AND METHODS FOR IMAGING AND TREATING ENDOMETRIOSIS Endomet Biosciences, Inc. (US) 2026-04-08 — — EP disclosed
EP-4720088-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS University of Georgia Research Foundation, Inc. (US) 2026-04-08 — — EP disclosed
US-4745124-A THIO/ESTER PEPTIDES UNIVERSITY OF MIAMI (US) 1988-05-17 — — US disclosed
WO-1988001618-A1 BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE GANSOW OTTO A (US) 1988-03-10 — — WO disclosed
EP-0220279-A1 METHOD OF FORMING A METAL CHELATE PROTEIN CONJUGATE GANSOW, Otto A. (US) 1987-05-06 — — EP disclosed
EP-0217286-A1 Phenylalanine derivative and proteinase inhibitor Okamoto, Shosuke (JP) 1987-04-08 — — EP disclosed
WO-1986006384-A1 METHOD OF FORMING A METAL CHELATE PROTEIN CONJUGATE GANSOW OTTO A (US) 1986-11-06 — — WO disclosed
EP-0117089-A1 Beta-adrenergic antagonist compounds and derivatives of beta-adrenergic antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1984-08-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612598-B2 Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy IL2, ICOS, IL2RA PPARA 2773/4885PPARG 3317/4885ACE 4748/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 PPARA 3818/4885PPARG 4330/4885ACE 140/4885
US-12624122-B2 Affinity maturated TAG72 specific single chain antibodies IGLV6-57, CD74, IGSF11 PPARA 2577/4885PPARG 4254/4885ACE 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.